Region:
All editions →MethodologyUpdated · October 2026
P
eupeptideguide
Find my vendor →
GIP/GLP-1 dual agonist research

Tirzepatide.
3 vendors · €40–90

Dual GIP/GLP-1 receptor agonist, FDA- and EMA-approved as Mounjaro and Zepbound. Research-vial tirzepatide is a different, unapproved product, not made or reviewed as those medicines, and not for human use.

Approved-analogue classLyophilised vialAlso known as:Mounjaro · Zepbound
Compound specification
Formula
C₂₂₅H₃₄₈N₄₈O₆₈
CAS
2023788-19-2
MW
4813 g/mol
Half-life
Approximately 5 days (human; Mounjaro prescribing information, section 12.3)
Storage
Lyophilised powder below −15 °C in a tightly closed container, shielded from light; equilibrate the sealed vial to room temperature before opening. Reconstituted vials 2–8 °C.
Sizes
10 mg, 15 mg
What it is

The compound. Origin, research and regulatory reality.

Tirzepatide is a synthetic dual GIP/GLP-1 receptor agonist developed by Eli Lilly: a 39-amino-acid peptide engineered from the native GIP sequence with a fatty-diacid moiety for albumin binding. The FDA approved it as Mounjaro for type 2 diabetes on 13 May 2022 and as Zepbound for chronic weight management on 8 November 2023; Mounjaro is also authorised by the EMA.

The SURPASS trial programme characterised its dual-receptor mechanism and glucose-lowering action in adults with type 2 diabetes, including SURPASS-1 (Rosenstock et al., 2021) and a head-to-head comparison with semaglutide (Frías et al., 2021). The SURMOUNT programme (Jastreboff et al., 2022) studied its effect on body weight in adults with obesity or overweight through the same mechanism.

As Mounjaro and Zepbound, tirzepatide is prescription-only, manufactured and reviewed under FDA and EMA oversight, and its US prescribing information carries a boxed warning for thyroid C-cell tumours observed in rats. Research-use-only tirzepatide vials sold outside that supply chain are not those products and have not been reviewed for safety, effectiveness or quality. The FDA has warned of fraudulently compounded tirzepatide and has warned companies that illegally sold unapproved tirzepatide falsely labelled ‘for research purposes’.

Live vendor register · grouped by strength

Every vendor. Cheapest per mg first, kits listed separately.

TIRZEPATIDE · price per mg
3 listings · unflagged vendors first · Listings data last updated October 2026

Best price per mg: Pepsup 30 mg at €3.00/mg.

5 mg

1 listing
01
PEAK_PEPTIDEVID-PEAK-PEP · AT dispatch · €39.90
5 mg
99.6%
Liquilabs per-batch COA · ICP-MS
In stock
Dispatch 24–48 h
€8.00/mg
€40
Go →

10 mg

1 listing
01
Adria ScienceVID-ADRIA-SC · SI/CZ dispatch · sold as GLP-2 (TR)
10 mg
99.8%
Liquilabs per-lot COA · USP<85>
In stock
Dispatch 1–3 days
€4.00/mg
€40
Go →

30 mg

1 listing
01
PepsupVID-PEPSUP · NL dispatch · €89.99 · 60 mg €149.99
30 mg
99%
No COA published (mfr claim 99%+)
In stock
NL 1–2 d · EU 2–5 d
€3.00/mg
€90
Go →
Representative literature

Research context. Recent peer-reviewed work.

2021 · Lancet
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1)
DOI ↗
2021 · N. Engl. J. Med.
Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2)
cited by n = 1879DOI ↗
2022 · N. Engl. J. Med.
Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1)
cited by n = 2539DOI ↗
Common questions

Frequently asked.

Is tirzepatide legal to buy?

Mounjaro and Zepbound are prescription-only medicines. Research-use-only tirzepatide vials are sold for laboratory research, not human use; RUO labelling does not make personal use or import legal everywhere.

How does research-vial tirzepatide differ from Mounjaro or Zepbound?

The approved pens are manufactured and reviewed under FDA/EMA oversight and carry a boxed thyroid-tumour warning based on reviewed safety data. Research vials come from an unreviewed supply chain with no verified purity or delivery controls.

What should a CoA show for tirzepatide?

HPLC purity, LC-MS mass confirmation matching C225H348N48O68 (MW ~4813), a lot number, an independent third-party lab name and a test date. The FDA has warned of fraudulently labelled compounded tirzepatide products.

Same research area

Similar compounds.

GH secretagogue research

Ipamorelin

Synthetic pentapeptide described in 1998 by Novo Nordisk researchers as a selective ghrelin/GH-secretagogue receptor agonist; researched for growth-hormone release. Not approved for human therapeutic use.
7 vendors€14–45
GHRH analogue research

CJC-1295

GHRH(1-29) analogue developed by ConjuChem; the DAC form binds albumin and persists for days, the no-DAC form (Mod GRF 1-29) is short-acting. Researched for GH/IGF-1 stimulation; not approved for human therapeutic use.
7 vendors€22–89
Fat metabolism research fragment

AOD-9604

Modified C-terminal fragment of human growth hormone (hGH 177–191). Researched for adipose-tissue mechanisms; not approved for human therapeutic use.
5 vendors€21–60
Triple hormone agonist research

Retatrutide

Investigational triple GIP/GLP-1/glucagon receptor agonist (LY3437943) developed by Eli Lilly and studied in Phase 3 trials; not approved as a medicine anywhere and not for human therapeutic use.
5 vendors€70–122
Amylin analogue research

Cagrilintide

Long-acting amylin-receptor agonist (AM833 / NNC0174-0833) developed by Novo Nordisk, studied alone and in the CagriSema combination; not approved as a medicine anywhere and not for human therapeutic use.
1 vendor€103
Long-form research guide

Weight Loss Research. Mechanism + protocols + safety.

Lipolysis, GH secretagogues, and adipose tissue modulation in obesity models

Open the long-form guide for Tirzepatide →